David Chernoff

3.7k total citations
69 papers, 2.8k citations indexed

About

David Chernoff is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, David Chernoff has authored 69 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Virology, 18 papers in Infectious Diseases and 16 papers in Epidemiology. Recurrent topics in David Chernoff's work include HIV Research and Treatment (24 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and HIV/AIDS drug development and treatment (14 papers). David Chernoff is often cited by papers focused on HIV Research and Treatment (24 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and HIV/AIDS drug development and treatment (14 papers). David Chernoff collaborates with scholars based in United States, Sweden and Netherlands. David Chernoff's co-authors include Morris Schambelan, Carl Grünfeld, Viva Tai, Heather A. Algren, Joan C. Lo, Kathleen Mulligan, Harry Hollander, Sean Farmer, Glenn R. Gibson and David Keller and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nucleic Acids Research.

In The Last Decade

David Chernoff

66 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Chernoff United States 28 945 901 706 628 456 69 2.8k
Carey L. Shive United States 24 559 0.6× 925 1.0× 536 0.8× 640 1.0× 105 0.2× 46 2.3k
Armin Rieger Austria 32 1.0k 1.1× 643 0.7× 1.1k 1.6× 459 0.7× 141 0.3× 123 3.6k
Stefan Eßer Germany 29 1.5k 1.6× 813 0.9× 852 1.2× 997 1.6× 100 0.2× 133 3.4k
Giuseppe Nunnari Italy 26 726 0.8× 1.1k 1.2× 573 0.8× 181 0.3× 82 0.2× 58 2.2k
Thomas Prindiville United States 26 700 0.7× 992 1.1× 1.0k 1.5× 244 0.4× 234 0.5× 64 3.3k
Cecilia M. Shikuma United States 35 2.3k 2.4× 2.0k 2.3× 959 1.4× 1.8k 2.8× 101 0.2× 156 4.2k
Brent E. Palmer United States 40 1.2k 1.3× 1.3k 1.4× 1.2k 1.7× 390 0.6× 191 0.4× 99 5.7k
Delphine Sauce France 28 799 0.8× 1.2k 1.3× 1.3k 1.9× 440 0.7× 143 0.3× 66 4.4k
Dag Kvale Norway 33 776 0.8× 674 0.7× 859 1.2× 389 0.6× 68 0.1× 101 3.7k
Ethan Bornstein United States 9 1.1k 1.1× 2.1k 2.3× 879 1.2× 695 1.1× 59 0.1× 9 3.4k

Countries citing papers authored by David Chernoff

Since Specialization
Citations

This map shows the geographic impact of David Chernoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chernoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chernoff more than expected).

Fields of papers citing papers by David Chernoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Chernoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chernoff. The network helps show where David Chernoff may publish in the future.

Co-authorship network of co-authors of David Chernoff

This figure shows the co-authorship network connecting the top 25 collaborators of David Chernoff. A scholar is included among the top collaborators of David Chernoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Chernoff. David Chernoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gaylis, Norman, David Sikes, Alan Kivitz, et al.. (2025). Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study. Rheumatology and Therapy. 12(6). 1125–1136.
2.
Natarajan, Chandramohan, et al.. (2024). Electrical stimulation of the vagus nerve ameliorates inflammation and disease activity in a rat EAE model of multiple sclerosis. Proceedings of the National Academy of Sciences. 121(28). e2322577121–e2322577121. 8 indexed citations
3.
D’Haens, Geert, Michael Eberhardson, Silvio Danese, et al.. (2023). Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study. Journal of Crohn s and Colitis. 17(12). 1897–1909. 33 indexed citations
4.
Poppel, Mireille N. M. van, Warren Boling, Jason M. Schwalb, et al.. (2023). AB0482 CLINICAL SAFETY AND FEASIBILITY OF A NOVEL IMPLANTABLE NEUROIMMUNE MODULATION DEVICE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 82. 1435–1435.
5.
6.
Cohen, Jeffrey A., Samuel F. Hunter, Theodore R. Brown, et al.. (2018). Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal. 25(4). 601–609. 8 indexed citations
7.
8.
9.
Leaker, Brian, Brian O’Connor, Peter J. Barnes, et al.. (2013). The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma. European Respiratory Journal. 42(Suppl 57). P1592–P1592. 1 indexed citations
10.
Centola, Michael, G. Cavet, Yijing Shen, et al.. (2013). Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLoS ONE. 8(4). e60635–e60635. 130 indexed citations
11.
12.
Allaart, C.F., Linda Dirven, Shintaro Hirata, et al.. (2011). A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study. Data Archiving and Networked Services (DANS). 1 indexed citations
13.
Elbeik, Tarek, W. Gregory Alvord, Rapee Trichavaroj, et al.. (2002). Comparative Analysis of HIV-1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV-1 RNA 3.0 Versus Roche Amplicor HIV-1 Monitor Version 1.5. JAIDS Journal of Acquired Immune Deficiency Syndromes. 29(4). 330–339. 52 indexed citations
14.
Lynn, Henry, Sharyne Donfield, Edward D. Gomperts, et al.. (2001). Hepatitis C Virus Load Is Associated with Human Immunodeficiency Virus Type 1 Disease Progression in Hemophiliacs. The Journal of Infectious Diseases. 183(4). 589–595. 102 indexed citations
15.
Lynn, Henry, Sharyne Donfield, Edward D. Gomperts, et al.. (2001). Relation Between HIV-1 and Hepatitis C Viral Load in Patients With Hemophilia. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 466–472. 87 indexed citations
16.
Haas, David W., et al.. (1998). Proinflammatory Cytokine and Human Immunodeficiency Virus RNA Levels during EarlyMycobacterium aviumComplex Bacteremia in Advanced AIDS. The Journal of Infectious Diseases. 177(6). 1746–1749. 14 indexed citations
17.
Deeks, Steven G., Robert L. Coleman, R. L. White, et al.. (1997). Variance of Plasma Human Immunodeficiency Virus Type 1 RNA Levels Measured by Branched DNA within and between Days. The Journal of Infectious Diseases. 176(2). 514–517. 28 indexed citations
18.
Chernoff, David, et al.. (1995). Oral histoplasmosis in HIV-infected patients. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 79(6). 710–714. 24 indexed citations
19.
Golden, Jeffrey A., et al.. (1993). A Randomized Comparison of Once-monthly or Twice-monthly High-dose Aerosolized Pentamidine Prophylaxis. CHEST Journal. 104(3). 743–750. 16 indexed citations
20.
Schiødt, Morten, Caroline L. Dodd, Deborah Greenspan, et al.. (1992). Natural history of HIV-associated salivary gland disease. Oral Surgery Oral Medicine Oral Pathology. 74(3). 326–331. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carey L. Shive Breakdown of academic impact, for papers by Armin Rieger Breakdown of academic impact, for papers by Stefan Eßer Breakdown of academic impact, for papers by Giuseppe Nunnari Breakdown of academic impact, for papers by Thomas Prindiville Breakdown of academic impact, for papers by Cecilia M. Shikuma Breakdown of academic impact, for papers by Brent E. Palmer Breakdown of academic impact, for papers by Delphine Sauce Breakdown of academic impact, for papers by Dag Kvale Breakdown of academic impact, for papers by Ethan Bornstein
Rankless by CCL
2026